Target intelligence / Profile preview

Human Immunodeficiency Virus type 1 Envelope Glycoprotein 41 (gp41)

Target
gp41
Molecular classification
Viral transmembrane glycoprotein
01

Overview

HIV envelope protein gp41 is a transmembrane glycoprotein that forms part of the HIV-1 envelope (Env) spike complex, which is essential for viral entry into host cells. The Env complex consists of three gp120 surface subunits non-covalently associated with three gp41 transmembrane subunits, forming a trimeric structure on the viral surface. gp41 mediates fusion between the viral envelope and host cell membranes following receptor engagement by gp120. Upon binding CD4 and coreceptor on target cells, conformational changes expose the hydrophobic fusion peptide of gp41, which inserts into the cellular membrane. Subsequent refolding brings together heptad repeat regions to form a stable six-helical bundle, drawing viral and cellular membranes together until they fuse—allowing entry of viral contents into the cell cytoplasm. Because formation of its characteristic helical bundles is essential for function, small molecules or peptides targeting these interfaces can block infection at an early stage. The high conservation within its ectodomain further supports its value as a drug/vaccine target.

02

Mechanism of action

Inhibition of gp41-mediated membrane fusion

03

Biological functions

Virus-cell membrane fusion
04

Disease associations

Infection
05

Safety considerations

Development of resistance to entry inhibitorsPotential for off-target effects of fusion inhibitors
06

Interacting drugs

Enfuvirtide/T20

Beyond the preview

Go deeper on Human Immunodeficiency Virus type 1 Envelope Glycoprotein 41 (gp41).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human Immunodeficiency Virus type 1 Envelope Glycoprotein 41 (gp41).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call